Monsanto dominated the battle over first-generation biotech seeds and traitsâ€”those largely focused on input traits such as" />
in this issue
Chemical Week Magazine :: Viewpoint
8:08 AM MDT | April 9, 2010
So Monsantoâ€™s seeds and trait sales and earnings wonâ€™t grow to the sky forever. Monsanto has had an impressive run since its 2000 spin off from Pharmacia, with profits and its market capitalization up more than fivefold. The mid-2008 commodity and financial bust pushed the stock off its peak, but a fierce customer push back on pricing now has the company ratcheting down earnings expectations. Monsanto dominated the battle over first-generation biotech seeds and traitsâ€”those largely focused on input traits such as...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee